Free Trial
OTCMKTS:PURE

PURE Bioscience 6/16/2025 Earnings Report

PURE Bioscience logo
$0.08 -0.01 (-6.52%)
As of 09/12/2025 12:45 PM Eastern

PURE Bioscience EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

PURE Bioscience Revenue Results

Actual Revenue
$0.49 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PURE Bioscience Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

PURE Bioscience Earnings Headlines

Trump's Law S.1582: $21T Dollar Revolution Coming
Do you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. If you do…tc pixel
See More PURE Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PURE Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PURE Bioscience and other key companies, straight to your email.

About PURE Bioscience

PURE Bioscience (OTCMKTS:PURE), Inc. is a San Diego, California–based company that develops and markets patented antimicrobial solutions for diverse industries. At the core of its technology portfolio is Silver Dihydrogen Citrate (SDC), an EPA-registered broad-spectrum biocide designed to neutralize bacteria, viruses, and fungi on contact. The company targets applications in food processing, water treatment, personal care, and medical device sanitation.

PURE’s product suite includes concentrate formulations and ready-to-use solutions. Its food safety line offers surface sanitizers and processing aids approved by the U.S. Department of Agriculture (USDA) and the Food and Drug Administration (FDA) for direct contact with food-contact surfaces. The company also supplies biocidal chemistries for incorporation into personal care products such as shampoos and topical washes, as well as specialty solutions for water disinfection.

Founded in 2001, PURE Bioscience holds a portfolio of patents covering the generation and stabilization of SDC, which it licenses globally through distribution partnerships. The company serves customers across North America, with growing penetration into international markets via strategic alliances. PURE continues to expand its product approvals and registrations, reinforcing its position in regulated sectors that require validated antimicrobial efficacy.

PURE’s leadership team combines expertise in microbiology, regulatory affairs, and commercial operations to guide product development and market expansion. By focusing on scalable manufacturing processes, rigorous quality controls, and regulatory compliance, PURE Bioscience aims to address evolving public health needs with science-driven antimicrobial solutions.

View PURE Bioscience Profile

More Earnings Resources from MarketBeat